Literature DB >> 11142177

Alzheimer's disease: clinical treatment options.

W E Reichman.   

Abstract

Comprehensive treatment of Alzheimer's disease (AD) requires thorough caregiver support and a thoughtful and informed use of medications for cognition enhancement, neuroprotection, and the treatment of disturbed behavior. Current treatments such as the cholinesterase inhibitors donepezil and rivastigmine can slow the progression of cognitive and functional deficits in AD over the short term. Sustained improvement and possible disease modification that result from the use of these medications are being evaluated in long-term studies. Treatment with alpha-tocopherol (vitamin E) has been shown to delay the progression of nursing home admission in patients with mild-to-moderate AD. Although antioxidant, anti-inflammatory, and other treatment strategies are promising, recent studies of the treatment of AD with estrogen or prednisone have produced disappointing results. For managing the behavioral symptoms that commonly accompany AD (e.g., delusions, aggression, depression, anxiety, irritability), various antipsychotics, antidepressants, and anticonvulsants have been effective in carefully selected patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11142177

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  4 in total

Review 1.  Estrogen and Alzheimer's disease: the story so far.

Authors:  Brenna Cholerton; Carey E Gleason; Laura D Baker; Sanjay Asthana
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Therapeutic approaches to age-associated neurocognitive disorders.

Authors:  R O'Hara; C Derouesné; K N Fountoulakis; J A Yesavage
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

3.  Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease.

Authors:  Francesco Chiappelli; Audrey M Navarro; David R Moradi; Ercolano Manfrini; Paolo Prolo
Journal:  Evid Based Complement Alternat Med       Date:  2006-11-10       Impact factor: 2.629

4.  Mechanism of anti-dementia effects of mangiferin in a senescence accelerated mouse (SAMP8) model.

Authors:  Zhengcai Du; Fangcao Fanshi; Yu-Heng Lai; Jung-Ren Chen; Erwei Hao; Jiagang Deng; Chung-Der Hsiao
Journal:  Biosci Rep       Date:  2019-09-20       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.